inflammatory bowel disease

Quotient Therapeutics and Merck partner on IBD drug discovery, with Quotient receiving $20M upfront and up to $2.2B in milestones.

VR Adviser increased Spyre Therapeutics stake by 1M shares to $120.74M. Stock surged 132% annually, but preclinical risks remain high for retail investors.

Seres Therapeutics swung to $5.7M 2025 profit from $125.8M loss, boosted by Nestlé VOWST sale, with $45.8M cash funding ops through Q3 2026.

Commodore Capital increases Spyre Therapeutics stake to $78.24M as stock surges 63% YoY. Biotech firm has $757M cash and expects Phase 2 data in 2026.

Abivax presented evidence that obefazimod shows anti-fibrotic potential in IBD treatment with good safety profile. Phase 3 results expected mid-2026.

Eli Lilly's Omvoh shows durable three-year remission in Crohn's disease, with 92.4% of patients maintaining clinical remission and reduced hospitalizations compared to placebo.

Teva and Sanofi report positive Phase 3 results for duvakitug IBD treatment, with over 55% of patients meeting efficacy endpoints. Stock rises 2.85%.

Teva and Sanofi's duvakitug showed sustained remission in phase 2b trial for inflammatory bowel disease, with remission rates of 41-58% depending on condition and dosage.

Sanofi and Teva's duvakitug showed sustained efficacy treating ulcerative colitis and Crohn's disease in a Phase 2b trial, supporting advancement to Phase 3 development.

Sanofi and Teva report duvakitug maintains efficacy in IBD maintenance trial, with remission rates of 47-58% in ulcerative colitis. Drug advances to Phase III development.